A great advance in the treatment of all CD20 positive B-cell lymphoproliferative disorders has been achieved by the addition of anti-CD20 monoclonal antibody Rituximab to standard chemotherapy. As a consequence, Rituximab has also greatly expanded the treatment options for patients with chronic lymphocytic leukemia (CLL), a “mature” B-cell malignancy characterized by an increase in marrow and circulating neoplastic B-lymphocytes. Interestingly, several autoimmune disorders are also successfully treated with Rituximab.
|Titolo:||Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia|
|Data di pubblicazione:||2015|
|Appare nelle tipologie:||1.1 Articoli su Rivista|